– USA, MA – Vascular Insights today announced that James (Chip) Draper has been appointed Chief Executive Officer and President. As Mr. Draper oversees global operations, James P. Ott, former CEO, has been appointed to a newly created Executive Chairman role. Mr. Ott will be focused on advisory, and special projects, at the request of the Board.
Mr. Draper joined the Vascular Insights team in January of 2014 as Vice President of Marketing. He has since contributed his years of experience in Leadership, Sales, Training, Strategic Marketing and Global Marketing to the expansion of Vascular Insights into more than 40 countries around the world.
Prior to joining Vascular Insights, Mr. Draper worked in multiple roles of progressive leadership responsibility at Covidien, Tyco Healthcare and Kendall Healthcare where he led the global expansion of the dialysis catheter portfolio. Prior to Covidien, he held leadership roles in executive search industry. A native of the Midwest, Mr. Draper holds a Master of Business Administration from Baker University and a Bachelor’s degree from Rockhurst University.
Mr. Draper commented, “I am incredibly proud of the success our team has achieved to date, which is a true testament to the combination of a great product, focused intent, and strong drive. With excellent evidence and clinical programs in place, and our continued focus on identifying efficiencies in our global operations, I am confident that ClariVein is well positioned to become a leader in the peripheral vascular device market.”
About Vascular Insights
Vascular Insights, LLC engages in the design, development, manufacturing and marketing of medical devices for the minimally invasive treatment of peripheral vascular disease. The ClariVein device has been used in more than 160,000 patients globally with excellent published results.
For more information : http://www.vascularinsights.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.